Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10767118 | 0.86 | POLB (0.47) | ACHELMNAALDH1A1POLBTSHR | |
| SCHEMBL25045333 | 0.73 | PDE7A (0.40) | ACHE | |
| SCHEMBL19766560 | 0.69 | PARP1 (0.35) | ACHEALDH1A1TSHRKMT2AGAA | |
| SCHEMBL17892788 | 0.68 | AKR1C3 (0.40) | ACHEPKMMEN1KMT2AAKR1C3 | |
| SCHEMBL17185334 | 0.67 | — | — | |
| SCHEMBL7539678 | 0.67 | CRBN (0.42) | ACHEALDH1A1 | |
| SCHEMBL6237189 | 0.66 | CTSG (0.45) | LMNAALDH1A1POLBTSHRNPSR1 | |
| SCHEMBL2176405 | 0.66 | DPP4 (0.43) | — | |
| SCHEMBL8341378 | 0.65 | PARP2 (0.42) | ACHELMNAALDH1A1TP53GAA | |
| SCHEMBL11120401 | 0.65 | OPRM1 (0.40) | PKMLMNAALDH1A1POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100145006-A1 | SUPRAVALENT COMPOUNDS | APLAGEN GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20090281278-A1 | MODIFIED MOLECULES WHICH PROMOTE HEMATOPOIESIS | APLAGEN GMBH (DE) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281278-A1 | MODIFIED MOLECULES WHICH PROMOTE HEMATOPOIESIS | EPOR, MPL, THPO | ACHE 4876/4885PKM 2205/4885LMNA 3707/4885 |
| US-20100145006-A1 | SUPRAVALENT COMPOUNDS | FCGR3B, FCGR2A, CD4 | ACHE 2636/4885PKM 4628/4885LMNA 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.